Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

Phase 1CompletedNCT03371342

Medy-Tox30 enrolled

Overview

To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Overactive Bladder

Interventions

MeditoxinDRUG

Meditoxin (Botulinum toxin type A)

BotoxDRUG

Botox(Botulinum toxin type A)

Eligibility

Sex: FEMALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female aged more than 20 years * Subject who has symptoms of Overactive Bladder for a period of at least 6 months immediately prior to screening Exclusion Criteria: \- Patient not appropriate for participating in this study according to the investigator's opinion

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Change from baseline in adverse events of MEDITOXIN at 12 week

safety profiles

Time frame: baseline, week 12 follow up visits

Secondary Outcomes

Change from baseline in the daily average number of episodes of urinary incontinence

Urinary incontinence recorded by the participants in a bladder diary during the 3 consecutive days prior to the study visit.

Time frame: baseline, week 12 follow up visits

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.